Vanadate inhibits liver fructose-2,6-bisphosphatase.

Eur J Biochem

Hormone and Metabolic Research Unit, International Institute of Cellular and Molecular Pathology, Brussels, Belgium.

Published: May 1990

Vanadate was found to be a reversible non-competitive inhibitor of chicken liver fructose-2,6-bisphosphatase. The inhibition was best observed in the presence of glycerol 2- or 3-phosphate and half-maximal effect was obtained with about 0.15 mM vanadate. Vanadate decreased the extent of phosphorylation of the enzyme (E-P) by fructose 2,6-[2-32P]bisphosphate. This did not result from an increased rate of E-P breakdown, as is the case with phosphoglycerate mutase, an enzyme which shares structural and functional similarity to fructose-2,6-bisphosphate. The data were consistent with the formation of a dead-end transition state analogue of phosphate in the active site. Inhibition of fructose-2,6-bisphosphatase by vanadate offers a likely explanation for the increase in fructose 2,6-bisphosphate concentration brought about by vanadate in isolated rat hepatocytes.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1432-1033.1990.tb15544.xDOI Listing

Publication Analysis

Top Keywords

liver fructose-26-bisphosphatase
8
fructose-26-bisphosphatase vanadate
8
vanadate
6
vanadate inhibits
4
inhibits liver
4
vanadate reversible
4
reversible non-competitive
4
non-competitive inhibitor
4
inhibitor chicken
4
chicken liver
4

Similar Publications

Objectives: Hepatocellular carcinoma (HCC) represents the third-most prevalent cancer in humans worldwide. The current study's objective is to search for the potentiality of H. Wendl () leaf extract in a nanoemulsion (NE) form in enhancing radiotherapy against HCC induced in rats using diethylnitrosamine (DEN).

View Article and Find Full Text PDF

Liver malignancies, particularly hepatocellular carcinoma (HCC), pose a formidable global health challenge. Conventional diagnostic techniques frequently fall short in precision, especially at advanced HCC stages. In response, we have developed a novel diagnostic strategy that integrates hyperspectral imaging with deep learning.

View Article and Find Full Text PDF

Background/purpose: Periodontitis is associated with systemic health. One of the underlying mechanisms is the translocation of periodontal pathogens, among which () is the most common. Here, we aimed to illustrate the biodistribution and dynamics of from gingiva to multiple organs through blood circulation.

View Article and Find Full Text PDF

Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy.

Life Metab

December 2024

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, Shaanxi 710032, China.

Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases and is mainly caused by metabolic disorders and systemic inflammatory responses. Recent studies have indicated that the activation of the mammalian (or mechanistic) target of rapamycin (mTOR) signaling participates in MASH progression by facilitating lipogenesis and regulating the immune microenvironment. Although several molecular medicines have been demonstrated to inhibit the phosphorylation or activation of mTOR, their poor specificity and side effects limit their clinical application in MASH treatment.

View Article and Find Full Text PDF

Spatial multi-omics characterizes GPR35-relevant lipid metabolism signatures across liver zonation in MASLD.

Life Metab

December 2024

Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, Liaoning 116023, China.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a metabolic disease that can progress to metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and cancer. The zonal distribution of biomolecules in the liver is implicated in mediating the disease progression. Recently, G-protein-coupled receptor 35 (GPR35) has been highlighted to play a role in MASLD, but the precise mechanism is not fully understood, particularly, in a liver-zonal manner.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!